PROTEOMICS AND METABOLOMICS SHARED RESOURCE Project Summary The Bioanalytical Laboratory Shared Resource scored as ?excellent? during the previous review. To reflect the evolving needs of Wake Forest Baptist Comprehensive Cancer Center (WFBCCC) members, it has since been restructured to form the Proteomics and Metabolomics Shared Resource (PMSR). This Shared Resource provides advanced mass spectrometry services, technologies, and scientific consultation for global and targeted proteomics, metabolomics and lipidomics studies. The PMSR specializes in discovery, identification, characterization, and quantification of biomolecules, including proteins, lipids and other metabolites by mass spectrometry and biochemical methods in a variety of biological specimens; chromatography of proteins, peptides, lipids, nucleic acids and chemical compounds; measurement of bioenergy metabolism; and targeted multiplex analysis using immunoassays. Assets of PMSR include 1) Three major mass spectrometry systems for metabolomics and lipidomics analysis, including a new Shimadzu LCMS-8050 LC/MS/MS System; 2) A newly-installed Thermo Q-Exactive HF mass spectrometer with data-independent acquisition and parallel reaction monitoring capabilities interfaced with a nanoLC system for proteomics analysis; 3) Access to a broad range of instruments and expertise at RTI Metabolomics, now part of a broad partnership with the WFBCCC and PMSR; and 4) Expertise of personnel. The PMSR is directed by Cristina M. Furdui, Ph.D., and Mark O. Lively, Ph.D., and currently employs four individuals (Jingyun Lee, Ph.D, Hanzhi Wu, Ph.D., Brian Fulp, B.S., and Mark Morris, B.S.) for a combined total of 2.7 FTE (1.15 CCSG FTEs requested). During the last full reporting year (11/1/2014 ? 10/31/2015), the PMSR supported the research of 24 faculty members of Wake Forest Baptist Medical Center and 6 external researchers, analyzing 2,116 samples (approximately 90% of PMSR capacity). Usage by WFBCCC members with peer-reviewed funding during this period was 47% (75% based on number of samples). The Institution's support of the PMSR is reflected in its investment of close to $1M for purchasing of new instrumentation and hiring of additional personnel, a significant cost-sharing that increases the value of the CCSG investment in PMSR. The Shared Resource is reviewed annually by the Institution's Centers and Cores Advisory Committee, which is within Biomedical Research Services and Administration, and reports to the Dean. In addition, quarterly meetings of the Shared Resource Directors are held and include reports/discussions on activity, best practices, enhanced capabilities, and administrative management techniques. These are chaired by Kounosuke Watabe, Ph.D., the Associate Director for Shared Resources. The WFBCCC Senior Leadership has the final responsibility for evaluating the effectiveness of PMSR in supporting the Cancer Center mission.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA012197-46
Application #
10092993
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
1997-02-01
Project End
2022-01-31
Budget Start
2021-02-01
Budget End
2022-01-31
Support Year
46
Fiscal Year
2021
Total Cost
Indirect Cost
Name
Wake Forest University Health Sciences
Department
Type
DUNS #
937727907
City
Winston-Salem
State
NC
Country
United States
Zip Code
27157
Yang, M; Forbes, M E; Bitting, R L et al. (2018) Incorporating blood-based liquid biopsy information into cancer staging: time for a TNMB system? Ann Oncol 29:311-323
Godwin, Ryan C; Gmeiner, William H; Salsbury Jr, Freddie R (2018) All-atom molecular dynamics comparison of disease-associated zinc fingers. J Biomol Struct Dyn 36:2581-2594
Votanopoulos, Konstantinos Ioannis; Bartlett, David; Moran, Brendan et al. (2018) PCI is Not Predictive of Survival After Complete CRS/HIPEC in Peritoneal Dissemination from High-Grade Appendiceal Primaries. Ann Surg Oncol 25:674-678
Lamar, Zanetta S; Dothard, Andrew; Kennedy, LeAnne et al. (2018) Hyperglycemia during first-line R-CHOP or dose adjusted R-EPOCH chemotherapy for non-Hodgkin lymphoma is prevalent and associated with chemotherapy alteration - a retrospective study. Leuk Lymphoma 59:1871-1877
Melvin, Ryan L; Xiao, Jiajie; Berenhaut, Kenneth S et al. (2018) Using correlated motions to determine sufficient sampling times for molecular dynamics. Phys Rev E 98:023307
Bhatt, Nikunj B; Pandya, Darpan N; Dezarn, William A et al. (2018) Practical Guidelines for Cerenkov Luminescence Imaging with Clinically Relevant Isotopes. Methods Mol Biol 1790:197-208
Gesell, Sabina B; Golden, Shannon L; Limkakeng Jr, Alexander T et al. (2018) Implementation of the HEART Pathway: Using the Consolidated Framework for Implementation Research. Crit Pathw Cardiol 17:191-200
Mao, Chengqiong; Qu, Ping; Miley, Michael J et al. (2018) P-glycoprotein targeted photodynamic therapy of chemoresistant tumors using recombinant Fab fragment conjugates. Biomater Sci 6:3063-3074
Bhatt, Nikunj B; Pandya, Darpan N; Rideout-Danner, Stephanie et al. (2018) A comprehensively revised strategy that improves the specific activity and long-term stability of clinically relevant 89Zr-immuno-PET agents. Dalton Trans 47:13214-13221
Andrews, Rachel N; Caudell, David L; Metheny-Barlow, Linda J et al. (2018) Fibronectin Produced by Cerebral Endothelial and Vascular Smooth Muscle Cells Contributes to Perivascular Extracellular Matrix in Late-Delayed Radiation-Induced Brain Injury. Radiat Res 190:361-373

Showing the most recent 10 out of 548 publications